The Changing Landscape of Breast Cancer: How Biology Drives Therapy
Breast cancer is the most prevalent life-threatening cancer in women. Optimizing therapy to increase cure rates in early stage disease, and improving life expectancy and palliation for advanced stages, are goals driving major areas of research. The armamentarium of targeted treatments for breast can...
Main Authors: | Sarah Friend, Melanie Royce |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-01-01
|
Series: | Medicines |
Subjects: | |
Online Access: | http://www.mdpi.com/2305-6320/3/1/2 |
Similar Items
-
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
by: Andrew D. Simmons, et al.
Published: (2020-03-01) -
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
by: Bijay Singh, et al.
Published: (2020-11-01) -
A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy
by: Shah Ashish P., et al.
Published: (2018-03-01) -
PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis
by: Wasyluk W, et al.
Published: (2021-05-01) -
Structural implications for selective targeting of PARPs
by: Jamin D. Steffen, et al.
Published: (2013-12-01)